Overview
Triple-A syndrome, also known as Allgrove syndrome, is characterized by the triad of achalasia, alacrima, and adrenal insufficiency, often accompanied by neurological deficits such as neurodevelopmental delays or epilepsy 1.Diagnosis
Key Diagnostic Criteria: Achalasia, alacrima, and adrenal insufficiency (primary adrenal insufficiency and aldosterone deficiency) 1.
Recommended Tests:
- Endocrine function tests including cortisol, ACTH stimulation test, and aldosterone levels.
- Genetic testing for mutations in the AAAS gene 1.Management
First-Line Treatments:
- Hormone replacement therapy: glucocorticoids (e.g., hydrocortisone) and mineralocorticoids (e.g., fludrocortisone) 1.
Adjunctive Treatments:
- Management of achalasia with pneumatic dilation or surgical myotomy.
- Supportive care for neurological symptoms, including anticonvulsants for seizures 1.Special Populations
Pediatrics: Early recognition and management of endocrine deficiencies are crucial to prevent long-term complications 1.Key Recommendations
Perform comprehensive endocrine evaluations including cortisol, ACTH stimulation test, and aldosterone levels to confirm adrenal insufficiency in suspected cases (Evidence: Moderate 1).
Initiate glucocorticoid and mineralocorticoid replacement therapy tailored to individual patient needs to manage adrenal insufficiency (Evidence: Moderate 1).
Consider genetic testing for AAAS gene mutations to confirm the diagnosis and assess carrier status in family members (Evidence: Moderate 1).References
1 Lam YY, Lo IF, Shek CC, Tong TM, Ng DK, Tong TF et al.. Triple-A syndrome--the first Chinese patient with novel mutations in the AAAS gene. Journal of pediatric endocrinology & metabolism : JPEM 2006. link